Global Liposomal Drug-delivery System 麻豆原创 Research Report 2023

Publication ID:

PB510236102

Publication Date:

October 31, 2023

Pages:

102

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Specialty Chemicals [2]

Manufacturing (Chemicals) [3]

Chemicals [4]

Description:

Liposomal Drug-delivery System is a pharmaceutical technology that encapsulates drugs within lipid-based vesicles called liposomes. These microscopic structures enhance the delivery of drugs to target tissues, improve drug stability, and control drug release rates. Liposomal drug delivery is used to enhance the therapeutic effects of medications, reduce side effects, and improve the solubility of poorly water-soluble drugs.
The global Liposomal Drug-delivery System market is projected to reach US$ 6503.3 million in 2029, increasing from US$ 3328 million in 2022, with the CAGR of 10.1% during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Liposomal Drug-delivery System market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Lipoid Kosmetik
Lucas Meyer Cosmetics
Nippon Fine Chemical
Enoc Solutions
Nanovec
Lipotec
Croda
H&A Pharmachem
Lipomize
ID bio
BioSpectrum
Derma Clinical
Kewpie Corporation
Nanohealth Biotech
Creative Biostructure
Phenbiox
NOF CORPORATION
KYOWA PHARMA CHEMICAL
Nikko Chemicals
Segment by Type
Liposome Vitamin
Liposome Ceramide
Liposome CoQ10
Others
Segment by Application
Medical
Cosmetics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Liposomal Drug-delivery System report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Liposomal Drug-delivery System 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Liposome Vitamin
1.2.3 Liposome Ceramide
1.2.4 Liposome CoQ10
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Liposomal Drug-delivery System 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Medical
1.3.3 Cosmetics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposomal Drug-delivery System 麻豆原创 Perspective (2018-2029)
2.2 Liposomal Drug-delivery System Growth Trends by Region
2.2.1 Global Liposomal Drug-delivery System 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Liposomal Drug-delivery System Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Liposomal Drug-delivery System Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Liposomal Drug-delivery System 麻豆原创 Dynamics
2.3.1 Liposomal Drug-delivery System Industry Trends
2.3.2 Liposomal Drug-delivery System 麻豆原创 Drivers
2.3.3 Liposomal Drug-delivery System 麻豆原创 Challenges
2.3.4 Liposomal Drug-delivery System 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liposomal Drug-delivery System Players by Revenue
3.1.1 Global Top Liposomal Drug-delivery System Players by Revenue (2018-2023)
3.1.2 Global Liposomal Drug-delivery System Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Liposomal Drug-delivery System 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Liposomal Drug-delivery System Revenue
3.4 Global Liposomal Drug-delivery System 麻豆原创 Concentration Ratio
3.4.1 Global Liposomal Drug-delivery System 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposomal Drug-delivery System Revenue in 2022
3.5 Liposomal Drug-delivery System Key Players Head office and Area Served
3.6 Key Players Liposomal Drug-delivery System Product Solution and Service
3.7 Date of Enter into Liposomal Drug-delivery System 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Liposomal Drug-delivery System Breakdown Data by Type
4.1 Global Liposomal Drug-delivery System Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Liposomal Drug-delivery System Forecasted 麻豆原创 Size by Type (2024-2029)
5 Liposomal Drug-delivery System Breakdown Data by Application
5.1 Global Liposomal Drug-delivery System Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Liposomal Drug-delivery System Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Liposomal Drug-delivery System 麻豆原创 Size (2018-2029)
6.2 North America Liposomal Drug-delivery System 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Liposomal Drug-delivery System 麻豆原创 Size by Country (2018-2023)
6.4 North America Liposomal Drug-delivery System 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liposomal Drug-delivery System 麻豆原创 Size (2018-2029)
7.2 Europe Liposomal Drug-delivery System 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Liposomal Drug-delivery System 麻豆原创 Size by Country (2018-2023)
7.4 Europe Liposomal Drug-delivery System 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liposomal Drug-delivery System 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Liposomal Drug-delivery System 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Liposomal Drug-delivery System 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Liposomal Drug-delivery System 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liposomal Drug-delivery System 麻豆原创 Size (2018-2029)
9.2 Latin America Liposomal Drug-delivery System 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Liposomal Drug-delivery System 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Liposomal Drug-delivery System 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liposomal Drug-delivery System 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Liposomal Drug-delivery System 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Liposomal Drug-delivery System 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Liposomal Drug-delivery System 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lipoid Kosmetik
11.1.1 Lipoid Kosmetik Company Detail
11.1.2 Lipoid Kosmetik Business Overview
11.1.3 Lipoid Kosmetik Liposomal Drug-delivery System Introduction
11.1.4 Lipoid Kosmetik Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.1.5 Lipoid Kosmetik Recent Development
11.2 Lucas Meyer Cosmetics
11.2.1 Lucas Meyer Cosmetics Company Detail
11.2.2 Lucas Meyer Cosmetics Business Overview
11.2.3 Lucas Meyer Cosmetics Liposomal Drug-delivery System Introduction
11.2.4 Lucas Meyer Cosmetics Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.2.5 Lucas Meyer Cosmetics Recent Development
11.3 Nippon Fine Chemical
11.3.1 Nippon Fine Chemical Company Detail
11.3.2 Nippon Fine Chemical Business Overview
11.3.3 Nippon Fine Chemical Liposomal Drug-delivery System Introduction
11.3.4 Nippon Fine Chemical Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.3.5 Nippon Fine Chemical Recent Development
11.4 Enoc Solutions
11.4.1 Enoc Solutions Company Detail
11.4.2 Enoc Solutions Business Overview
11.4.3 Enoc Solutions Liposomal Drug-delivery System Introduction
11.4.4 Enoc Solutions Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.4.5 Enoc Solutions Recent Development
11.5 Nanovec
11.5.1 Nanovec Company Detail
11.5.2 Nanovec Business Overview
11.5.3 Nanovec Liposomal Drug-delivery System Introduction
11.5.4 Nanovec Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.5.5 Nanovec Recent Development
11.6 Lipotec
11.6.1 Lipotec Company Detail
11.6.2 Lipotec Business Overview
11.6.3 Lipotec Liposomal Drug-delivery System Introduction
11.6.4 Lipotec Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.6.5 Lipotec Recent Development
11.7 Croda
11.7.1 Croda Company Detail
11.7.2 Croda Business Overview
11.7.3 Croda Liposomal Drug-delivery System Introduction
11.7.4 Croda Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.7.5 Croda Recent Development
11.8 H&A Pharmachem
11.8.1 H&A Pharmachem Company Detail
11.8.2 H&A Pharmachem Business Overview
11.8.3 H&A Pharmachem Liposomal Drug-delivery System Introduction
11.8.4 H&A Pharmachem Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.8.5 H&A Pharmachem Recent Development
11.9 Lipomize
11.9.1 Lipomize Company Detail
11.9.2 Lipomize Business Overview
11.9.3 Lipomize Liposomal Drug-delivery System Introduction
11.9.4 Lipomize Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.9.5 Lipomize Recent Development
11.10 ID bio
11.10.1 ID bio Company Detail
11.10.2 ID bio Business Overview
11.10.3 ID bio Liposomal Drug-delivery System Introduction
11.10.4 ID bio Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.10.5 ID bio Recent Development
11.11 BioSpectrum
11.11.1 BioSpectrum Company Detail
11.11.2 BioSpectrum Business Overview
11.11.3 BioSpectrum Liposomal Drug-delivery System Introduction
11.11.4 BioSpectrum Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.11.5 BioSpectrum Recent Development
11.12 Derma Clinical
11.12.1 Derma Clinical Company Detail
11.12.2 Derma Clinical Business Overview
11.12.3 Derma Clinical Liposomal Drug-delivery System Introduction
11.12.4 Derma Clinical Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.12.5 Derma Clinical Recent Development
11.13 Kewpie Corporation
11.13.1 Kewpie Corporation Company Detail
11.13.2 Kewpie Corporation Business Overview
11.13.3 Kewpie Corporation Liposomal Drug-delivery System Introduction
11.13.4 Kewpie Corporation Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.13.5 Kewpie Corporation Recent Development
11.14 Nanohealth Biotech
11.14.1 Nanohealth Biotech Company Detail
11.14.2 Nanohealth Biotech Business Overview
11.14.3 Nanohealth Biotech Liposomal Drug-delivery System Introduction
11.14.4 Nanohealth Biotech Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.14.5 Nanohealth Biotech Recent Development
11.15 Creative Biostructure
11.15.1 Creative Biostructure Company Detail
11.15.2 Creative Biostructure Business Overview
11.15.3 Creative Biostructure Liposomal Drug-delivery System Introduction
11.15.4 Creative Biostructure Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.15.5 Creative Biostructure Recent Development
11.16 Phenbiox
11.16.1 Phenbiox Company Detail
11.16.2 Phenbiox Business Overview
11.16.3 Phenbiox Liposomal Drug-delivery System Introduction
11.16.4 Phenbiox Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.16.5 Phenbiox Recent Development
11.17 NOF CORPORATION
11.17.1 NOF CORPORATION Company Detail
11.17.2 NOF CORPORATION Business Overview
11.17.3 NOF CORPORATION Liposomal Drug-delivery System Introduction
11.17.4 NOF CORPORATION Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.17.5 NOF CORPORATION Recent Development
11.18 KYOWA PHARMA CHEMICAL
11.18.1 KYOWA PHARMA CHEMICAL Company Detail
11.18.2 KYOWA PHARMA CHEMICAL Business Overview
11.18.3 KYOWA PHARMA CHEMICAL Liposomal Drug-delivery System Introduction
11.18.4 KYOWA PHARMA CHEMICAL Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.18.5 KYOWA PHARMA CHEMICAL Recent Development
11.19 Nikko Chemicals
11.19.1 Nikko Chemicals Company Detail
11.19.2 Nikko Chemicals Business Overview
11.19.3 Nikko Chemicals Liposomal Drug-delivery System Introduction
11.19.4 Nikko Chemicals Revenue in Liposomal Drug-delivery System Business (2018-2023)
11.19.5 Nikko Chemicals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Lipoid Kosmetik
Lucas Meyer Cosmetics
Nippon Fine Chemical
Enoc Solutions
Nanovec
Lipotec
Croda
H&A Pharmachem
Lipomize
ID bio
BioSpectrum
Derma Clinical
Kewpie Corporation
Nanohealth Biotech
Creative Biostructure
Phenbiox
NOF CORPORATION
KYOWA PHARMA CHEMICAL
Nikko Chemicals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.